These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 35965504)

  • 1. The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma.
    Zhang J; Li R; Huang S
    Front Oncol; 2022; 12():951019. PubMed ID: 35965504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Olaoba OT; Yang M; Adelusi TI; Maidens T; Kimchi ET; Staveley-O'Carroll KF; Li G
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought.
    Agostini A; Orlacchio A; Carbone C; Guerriero I
    Front Immunol; 2022; 13():876291. PubMed ID: 35711414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components.
    Hsu SK; Jadhao M; Liao WT; Chang WT; Hung CT; Chiu CC
    Front Mol Biosci; 2022; 9():1020888. PubMed ID: 36299300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing the TME to improve the efficacy of cancer therapy.
    Bilotta MT; Antignani A; Fitzgerald DJ
    Front Immunol; 2022; 13():954992. PubMed ID: 36341428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
    Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
    Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new era: tumor microenvironment in chemoresistance of pancreatic cancer.
    Zhao X; Li Z; Gu Z
    J Cancer Sci Clin Ther; 2022; 6(1):61-86. PubMed ID: 35187493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
    Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
    Front Immunol; 2021; 12():643529. PubMed ID: 33679807
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.
    Wang S; Li Y; Xing C; Ding C; Zhang H; Chen L; You L; Dai M; Zhao Y
    Am J Cancer Res; 2020; 10(7):1937-1953. PubMed ID: 32774994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic Tumor Microenvironment.
    Wang K; He H
    Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
    Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
    EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreas adenocarcinoma: novel therapeutics.
    Krantz BA; Yu KH; O'Reilly EM
    Chin Clin Oncol; 2017 Jun; 6(3):30. PubMed ID: 28705007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
    Lafaro KJ; Melstrom LG
    Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
    Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
    Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDAC, the Influencer Cancer: Cross-Talk with Tumor Microenvironment and Connected Potential Therapy Strategies.
    Mercanti L; Sindaco M; Mazzone M; Di Marcantonio MC; Piscione M; Muraro R; Mincione G
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.